These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33675895)

  • 1. Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs.
    Chauhan A; Kumar M; Kumar A; Kanchan K
    Life Sci; 2021 Jun; 274():119301. PubMed ID: 33675895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New potential drug leads against MDR-MTB: A short review.
    Gatadi S; Nanduri S
    Bioorg Chem; 2020 Jan; 95():103534. PubMed ID: 31884135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015.
    Zhang Y; Yew WW
    Int J Tuberc Lung Dis; 2015 Nov; 19(11):1276-89. PubMed ID: 26467578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchronization of Mycobacterium life cycle: A possible novel mechanism of antimycobacterial drug resistance evolution and its manipulation.
    Verma H; Chauhan A; Kumar A; Kumar M; Kanchan K
    Life Sci; 2024 Jun; 346():122632. PubMed ID: 38615748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The resumption of consumption -- a review on tuberculosis.
    Ducati RG; Ruffino-Netto A; Basso LA; Santos DS
    Mem Inst Oswaldo Cruz; 2006 Nov; 101(7):697-714. PubMed ID: 17160276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of resistance in multi drug resistant tuberculosis patients.
    Irfan S; Hassan Q; Hasan R
    J Pak Med Assoc; 2006 Sep; 56(9):397-400. PubMed ID: 17091751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Multi-Drug Resistant
    Ali S; Khan MT; Khan AS; Mohammad N; Khan MM; Ahmad S; Noor S; Jabbar A; Daire C; Hassan F
    Pol J Microbiol; 2020; 69(2):1-5. PubMed ID: 32249555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control.
    Jabeen K; Shakoor S; Malik F; Hasan R
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():47-8. PubMed ID: 27128617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
    Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
    BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug resistance in Mycobacterium tuberculosis: contribution of constituent and acquired mechanisms].
    Gómez-Tangarife VJ; Gómez-Restrepo AJ; Robledo-Restrepo J; Hernández-Sarmiento JM
    Rev Salud Publica (Bogota); 2018; 20(4):491-497. PubMed ID: 30843986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
    Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B
    PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
    Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
    Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct Detection by the Xpert MTB/RIF Assay and Characterization of Multi and Poly Drug-Resistant Tuberculosis in Guinea-Bissau, West Africa.
    Rabna P; Ramos J; Ponce G; Sanca L; Mané M; Armada A; Machado D; Vieira F; Gomes VF; Martins E; Colombatti R; Riccardi F; Perdigão J; Sotero J; Portugal I; Couto I; Atouguia J; Rodrigues A; Viveiros M
    PLoS One; 2015; 10(5):e0127536. PubMed ID: 26017968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in
    Eoh H; Liu R; Lim J; Lee JJ; Sell P
    Front Cell Infect Microbiol; 2022; 12():958240. PubMed ID: 36072228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.